SMi's 4th Annual 3D Cell Culture

SMi Group 19 - 20 February 2020, London, UK.
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

SMi's 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.

Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.

For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech's and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.

Featured speakers include

  • Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, MHRA
  • Veronique Barban, Expert Virology, Research and Nonclinical Safety Department, Sanofi Pasteur
  • Simone Stahl, Associate Principal Scientist, ADME Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca
  • Wendy Rowan, Scientific Director, Novel Human Genetics Research Unit, GSK
  • Jason Ekert, Head of Complex In Vitro Models, GSK
  • Samuel Jackson, Programme Manager, Disease Models Efficacy and Safety Pharmacology, NC3RS

Key topics include

  • Learn from leading pharma companies to benchmark against their applications of 3D technology
  • Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
  • Hear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models
  • Discuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research
  • Participate in a panel discussion on adopting new technologies for 3D models

For more information and to register, please visit:
http://www.3D-cellculture.com/wpnWL

Early-Bird Rates

  • Register by 29th November to save £200
  • Register by 29th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...